These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17141785)

  • 41. Intraperitoneal insulin infusion: treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia.
    van Dijk PR; Logtenberg SJ; Gans RO; Bilo HJ; Kleefstra N
    Clin Endocrinol (Oxf); 2014 Oct; 81(4):488-97. PubMed ID: 25041605
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicentre trial of a programmable implantable insulin pump in type I diabetes. The Point Study II Group.
    Int J Artif Organs; 1995 Jun; 18(6):322-5. PubMed ID: 8593967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. After 6years of intraperitoneal insulin administration IGF-I concentrations in T1DM patients are at low-normal level.
    van Dijk PR; Logtenberg SJ; Chisalita SI; Hedman CA; Groenier KH; Gans RO; Kleefstra N; Arnqvist HJ; Bilo HJ
    Growth Horm IGF Res; 2015 Dec; 25(6):316-9. PubMed ID: 26336814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low subcutaneous degradation and slow absorption of insulin in insulin-dependent diabetic patients during continuous subcutaneous insulin infusion at basal rate.
    Chisholm DJ; Kraegen EW; Hewett MJ; Furler S
    Diabetologia; 1984 Aug; 27(2):238-41. PubMed ID: 6386586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intraperitoneal insulin absorption after long-term intraperitoneal insulin therapy.
    Scavini M; Pincelli A; Petrella G; Galimberti G; Zager PG; Torri M; Pozza G
    Diabetes Care; 1995 Jan; 18(1):56-9. PubMed ID: 7698048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continuous intraperitoneal insulin infusion: an alternative route for insulin delivery in type 1 diabetes.
    Pasquini S; Da Prato G; Tonolo G; Bonora E; Trombetta M
    Acta Diabetol; 2020 Jan; 57(1):101-104. PubMed ID: 31399782
    [No Abstract]   [Full Text] [Related]  

  • 47. Intraperitoneal insulin therapy in patients with type 1 diabetes. Does it fit into the current therapeutic arsenal?
    Giménez M; Purkayajtha S; Moscardó V; Conget I; Oliver N
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Mar; 65(3):182-184. PubMed ID: 29429951
    [No Abstract]   [Full Text] [Related]  

  • 48. Experience of long-term intraperitoneal insulin treatment using a new percutaneous access device.
    Wredling R; Adamson U; Lins PE; Backman L; Lundgren D
    Diabet Med; 1991 Jul; 8(6):597-600. PubMed ID: 1832367
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems.
    Olsen CL; Chan E; Turner DS; Iravani M; Nagy M; Selam JL; Wong ND; Waxman K; Charles MA
    Diabetes Care; 1994 Mar; 17(3):169-76. PubMed ID: 8174443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Continuous intraperitoneal insulin infusion in the management of severely brittle diabetes--a metabolic and clinical comparison with intravenous infusion.
    Husband DJ; Marshall SM; Walford S; Hanning I; Wright PD; Alberti KG
    Diabet Med; 1984 Jul; 1(2):99-104. PubMed ID: 6242795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peritoneal and subcutaneous absorption of insulin in type I diabetic subjects.
    Giacca A; Caumo A; Galimberti G; Petrella G; Librenti MC; Scavini M; Pozza G; Micossi P
    J Clin Endocrinol Metab; 1993 Sep; 77(3):738-42. PubMed ID: 8370695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Subcutaneous insulin infusion: change in basal infusion rate has no immediate effect on insulin absorption rate.
    Hildebrandt P; Birch K; Jensen BM; Kühl C
    Diabetes Care; 1986; 9(6):561-4. PubMed ID: 3542448
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of different insulin administration modalities on vitamin D metabolism of insulin-dependent diabetic patients.
    Colette C; Monnier L; Arnal J; Selam JL; Mirouze J
    Adv Exp Med Biol; 1986; 208():501-8. PubMed ID: 3551545
    [No Abstract]   [Full Text] [Related]  

  • 54. Insulin responses to varying profiles of subcutaneous insulin infusion: kinetic modelling studies.
    Kraegen EW; Chisholm DJ
    Diabetologia; 1984 Mar; 26(3):208-13. PubMed ID: 6370771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Absorption of subcutaneously infused insulin: influence of the basal rate pulse interval.
    Hildebrandt P; Birch K; Jensen BM; Kühl C; Brange J
    Diabetes Care; 1985; 8(3):287-9. PubMed ID: 3891269
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reversible focal hepatic steatosis in type 1 diabetic patients treated with intraperitoneal insulin implantable pump therapy.
    Meyer L; Jeantroux J; Riveline JP; Moreau F; Boivin S; Moser T; Pinget M; Jeandidier N
    Diabetes Care; 2008 Jun; 31(6):e49. PubMed ID: 18509136
    [No Abstract]   [Full Text] [Related]  

  • 57. Continuous subcutaneous insulin infusion in toddlers.
    Rami B; Nachbaur E; Waldhoer T; Schober E
    Eur J Pediatr; 2003 Oct; 162(10):721-2. PubMed ID: 12928895
    [No Abstract]   [Full Text] [Related]  

  • 58. Continuous subcutaneous insulin infusion corrects exercise-induced albuminuria in juvenile diabetes.
    Koivisto VA; Huttunen NP; Vierikko P
    Br Med J (Clin Res Ed); 1981 Mar; 282(6266):778-9. PubMed ID: 6783168
    [No Abstract]   [Full Text] [Related]  

  • 59. Optimal routes for chronic insulin infusion with portable and implantable devices.
    Selam JL; Slingeneyer A; Saeidi S; Mirouze J
    Artif Organs; 1984 Nov; 8(4):489-94. PubMed ID: 6391439
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Basal rate subcutaneous insulin infusion: absorption kinetics and relation to local blood flow.
    Hildebrandt P; Birch K
    Diabet Med; 1988; 5(5):434-40. PubMed ID: 2970915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.